Mechanosensitive Piezo ion channels, specifically Piezo1 and Piezo2, are being recognized as central regulators of digestive system physiology and disease, according to a comprehensive review published on Aug. 7. The review outlines how these channels convert mechanical forces such as tissue stretching, fluid flow, and pressure into cellular signals that influence gastrointestinal motility, secretion, barrier integrity, immune responses, and cancer progression. The findings suggest that Piezo channels could serve as biomarkers and therapeutic targets for a range of digestive disorders.
Since their identification in 2010, Piezo1 and Piezo2 have been found to function as critical mechanosensors that respond to physical stimuli by allowing calcium and sodium ions into cells. This influx activates signaling pathways involved in regulating cell behavior, tissue adaptation, and inflammatory responses. In the digestive tract specifically, these channels help coordinate essential physiological processes including appetite control, intestinal movement, bile secretion, and interactions with gut microbiota.
The review details the distinct but complementary roles of the two channel types: Piezo1 is broadly distributed throughout digestive tissues such as the stomach, liver, pancreas, intestinal epithelium, and enteric nervous system. It regulates functions like ghrelin secretion, peristalsis of the intestine, mucus production, bile flow regulation, and maintenance of microbial balance. In contrast, Piezo2 is more specialized for sensory pathways—mediating mechanosensation along with serotonin release for visceral pain perception and gastrointestinal reflexes.
A major feature described is how activation of these channels leads to stimulation of intracellular networks through calcium influx—triggering MAPK-, RhoA/ROCK-, PI3K-Akt-, and YAP/TAZ-mediated pathways that link mechanical stress to cell proliferation or migration as well as inflammation or tissue remodeling. This helps explain how abnormal mechanical environments can contribute to disease development.
The review connects dysregulation of these channels with several diseases: elevated Piezo1 expression in hepatocellular carcinoma promotes tumor invasion through FAK/Src signaling; both channel types contribute to gastric cancer progression; while in colorectal cancer they support stem-cell maintenance or lymphangiogenesis via SLIT2/ROBO1/VEGFC pathway involvement. Similar mechanisms are implicated in inflammatory bowel disease where activation amplifies inflammation by engaging NF-κB or NLRP3 inflammasome pathways.
Although therapeutic targeting remains at an early stage—with experimental compounds showing promise—challenges remain due to widespread expression across body tissues. Approaches involving organoids or gene-silencing technologies may improve specificity going forward.
